1. Home
  2. ASTH vs CAPR Comparison

ASTH vs CAPR Comparison

Compare ASTH & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Astrana Health Inc.

ASTH

Astrana Health Inc.

HOLD

Current Price

$22.01

Market Cap

1.4B

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$24.39

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTH
CAPR
Founded
1994
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ASTH
CAPR
Price
$22.01
$24.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
8
Target Price
$40.78
$41.38
AVG Volume (30 Days)
553.4K
1.2M
Earning Date
03-02-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.20
N/A
Revenue
$2,896,452,000.00
$11,130,509.00
Revenue This Year
$58.46
N/A
Revenue Next Year
$25.59
$16,329.74
P/E Ratio
$108.92
N/A
Revenue Growth
68.17
N/A
52 Week Low
$20.12
$4.30
52 Week High
$39.97
$40.37

Technical Indicators

Market Signals
Indicator
ASTH
CAPR
Relative Strength Index (RSI) 40.09 53.25
Support Level $20.92 $21.75
Resistance Level $22.97 $24.93
Average True Range (ATR) 1.53 1.32
MACD -0.59 -0.16
Stochastic Oscillator 20.79 73.49

Price Performance

Historical Comparison
ASTH
CAPR

About ASTH Astrana Health Inc.

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: